Our Company

Management Team

 

Mark Strobeck, Ph.D.

President and Chief Executive Officer

Dr. Strobeck has held leadership positions in both emerging biotechnology and pharmaceutical companies for more than twenty years. Most recently, he served as Managing Director of Aquilo Partners, LP, a life sciences investment bank. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla’s Chief Business Officer. He served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc.. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati and completed his post-doctoral fellowship at the University of Pennsylvania.


Russell Skibsted

Russell L. Skibsted

Executive Vice President, Chief Financial Officer and Chief Business Officer

Russell L. Skibsted has served as our Executive Vice President, Chief Financial Officer and Chief Business Officer since September 2020.

Mr. Skibsted is a seasoned executive with more than 25 years of experience in finance, global business development, capital raising, investor relations, and operations. He has worked with a variety of both public and private life sciences companies, from commercial stage, development stage and start up. Prior to joining Rockwell, he served as CFO of AgeX Therapeutics (NYSE American: AGE), a biotechnology company focused on cell therapy targeting the diseases of aging that was spun out of BioTime, Inc. (currently Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX)). Previously, Mr. Skibsted served as CFO of BioTime, Inc., a publicly-traded biotechnology company which he joined in 2015, where he simultaneously, from time to time, performed the role of Chief Financial Officer for several of BioTime’s public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer (November 2015 through November 2017) and Asterias Biotherapeutics, Inc., a biotechnology company pioneering the field of regenerative medicine with clinical programs in spinal cord injury and oncology immunotherapy(March 2016 through November 2016). Prior to BioTime, Mr. Skibsted served as CFO or Chief Business Officer for several public and private life science companies, including Proove Biosciences, Aeolus Pharmaceuticals, Spectrum Pharmaceuticals and Hana Biosciences. From time to time, he also acted as a consulting CFO to various life science companies as Managing Director of RSL Ventures. Earlier in his career, Mr. Skibsted held roles as Portfolio Management Partner and CFO at Asset Management Company, one of the oldest and most respected venture capital firms in Silicon Valley, and Vice President for GE Capital Services Structured Finance Group. Mr. Skibsted holds a B.A. in Economics from Claremont McKenna College and an M.B.A. from the Stanford Graduate School of Business.


Marc Hoffman

Marc Hoffman, M.D.

Chief Medical Officer

Dr. Hoffman has served as our Chief Medical Officer since November 2019. He has extensive experience in global drug development, medical affairs, pharmacovigilance and regulatory affairs, and has a proven track record in building, managing and globalizing medical teams for pharmaceutical companies; through both in-house roles at companies such as Baxter and Hospira and in senior leadership positions at various global contract research organizations (CROs), including Covance and, Parexel. Prior to joining Rockwell, Dr. Hoffman served as Chief Medical Officer at Celerion, Inc, a leader in early phase development and Patient iP, providing clinical leadership around Patient iP’s innovative platform, customer programs, and related medical affairs activities. Dr. Hoffman has also held the roles of Chief Medical Officer and Senior Vice President & General Manager over the Biopharmaceutical Business Unit at Theorem Clinical Research, leading the development of drugs and biologics.

Throughout his distinguished 30-year career, Dr. Hoffman has established medical capabilities in order to harness the data needed to develop and commercialize pharmaceutical products worldwide.

Dr Hoffman received his bachelor’s degree in psychology from Emory University and his MD from American University of the Caribbean. He went on to complete the Diploma in Pharmaceutical Medicine (DipPharmMed) organized jointly by BrAPP (British Association of Pharmaceutical Physicians) and Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University.


Megan Timmins

Megan Timmins

Senior Vice President, General Counsel and Corporate Secretary

Megan Timmins has served as our Senior Vice President, General Counsel and Corporate Secretary since August 2021, bringing over twenty years of legal experience, including six years in the life sciences industry. She previously served as Senior Vice President, General Counsel, and Corporate Secretary at Assertio Holdings, Inc. and Zyla Life Sciences (formerly Egalet Corporation), both publicly traded pharmaceutical companies. Ms. Timmins also held a high-level legal role at Aramark (NYSE: ARMK) as Vice President, Associate General Counsel and Assistant Corporate Secretary. Early in her legal career, she worked in private practice, including with Morgan, Lewis & Bockius, LLP.

Ms. Timmins holds a B.A. from the University of Notre Dame and a J.D. from William and Mary Law School.


Timothy T. Chole

Timothy T. Chole

Senior Vice President of Sales and Marketing

Mr. Chole has served as our SVP of Sales and Marketing since February 2021 and previously served as VP of Marketing since December 2019.

Mr. Chole brings over two decades of experience in commercial leadership roles for pharmaceutical and medical device companies. He has a proven track record of success launching products and growing mature portfolios; many of which have been therapeutics or devices for treatment of renal disease. Early in his career he served as the marketing lead for the IV iron portfolio at Watson Pharmaceuticals (now Allergan), and later was the Global Marketing Director for AKI Therapy at Gambro AB (now Baxter International Inc.). Mr. Chole’s background includes global, international, and U.S. marketing leadership and market development roles. Most recently served the Director of Product Marketing and Professional Education for hearing implants at Cochlear Americas.

Throughout his distinguished career, Mr. Chole has demonstrated expertise in strategic planning, product marketing excellence, new market development, KOL engagement, product launches, and commercial execution.

Mr. Chole received a Bachelor of Science degree in managerial economics from the University of California at Davis.


Michael DeYoung

Michael DeYoung

Vice President of Operations

Michael DeYoung has served as our Vice President of Operations since December 2018. Mr. DeYoung is responsible for leading Rockwell Medical’s Operations team, where he oversees manufacturing operations, logistics and company-wide strategy deployment, specifically for the launch of Triferic® in the U.S. and globally.

Mr. DeYoung’s experience includes more than 25 years in operations and finance. Before joining Rockwell Medical, he served as Chief Financial Officer of ZDHF Holdings, and as the Group Director of Moog Medical Device Group, where he was responsible for finance, human resources and IT operations, and played a key role in the turnaround of the division.

Mr. DeYoung also worked at Gambro AB, where he led operational initiatives contributing to the successful exit and sale of the company to Baxter International and was responsible for the full integration of the Baxter and Gambro renal operations in Latin America.

Mr. DeYoung received his bachelor’s in business management, general business from Western Michigan University and his master’s in accounting from Walsh College.